Steven Frank

Steven Frank is a declared insider at 2 companies (board member); the most frequent names are Precigen, Inc. and Biocryst Pharmaceuticals Inc. Over a trading history stretching from 22 February 2022 to 11 June 2026, the count stands at 18 filings.

The open-market record is one-sided, with 1 purchase worth €631k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 13 share grants and 4 option exercises.

The newest entry dates from 15 June 2026: a share grant, in Biocryst Pharmaceuticals Inc. The clock since the last published purchase (15 August 2023) now reads 1,160 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.